Showing 2,864 results

Filters Content type: News, Editors' picks Topic: PrEP

Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP).

Global health targets

More Europeans are dying from HIV now than 15 years ago

News
21 October 2025
Pharmaceutical industry

HIV Preventive Treatment Could Be Sold for One Thousandth of Current List Price

Editor's pick
Infectious Disease Society of America
21 October 2025
PrEP programmes & uptake

Europe: Final report from the audit of the HIV pre-exposure prophylaxis standards of care

Editor's pick
European Centre for Disease Prevention and Control (ECDC)
21 October 2025
PrEP programmes & uptake

HIV rates are highest in the American South, despite effective treatments – a clash between culture and public health

Editor's pick
The Conversation
17 October 2025
PrEP policies & guidelines

NICE approves annual access to injectable cabotegravir PrEP in England for 1000 people

Editor's pick
i-Base
17 October 2025
PrEP policies & guidelines

NHS to roll out first long-acting injection to prevent HIV

Editor's pick
NHS England
17 October 2025
Injectable & long-acting PrEP

The six-monthly anti-HIV jab is coming. But can South Africa keep track of millions of users?

Editor's pick
Bhekisisa
9 October 2025
PrEP science

Cabotegravir PrEP Implant Might Prevent HIV for a Year

Editor's pick
POZ
2 October 2025
PrEP policies & guidelines

Joint Statement: Activists Demand $40-a-Year Generic Price for Breakthrough HIV Prevention Drug Be Made Available to All Low- and Middle Income Countries

Editor's pick
Treatment Action Group
25 September 2025
PrEP policies & guidelines

Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily HIV prevention pill

Editor's pick
Bhekisisa
24 September 2025
Injectable & long-acting PrEP

Support for Indian Manufacturers to Produce Cheap Generics of HIV ‘Miracle’ Drug, Lenacapavir

Editor's pick
Health Policy Watch
24 September 2025
Injectable & long-acting PrEP

From Bench to Breakthrough: How Curiosity Led to an Extraordinarily Effective HIV Drug

Editor's pick
University of Utah
24 September 2025
Injectable & long-acting PrEP

CDC 'strongly' backs Gilead's HIV PrEP Yeztugo, but advocacy groups say access barriers remain

Editor's pick
FiercePharma
23 September 2025
PrEP policies & guidelines

UK: Pharmacies must be part of national HIV prevention strategies, researchers urge

Editor's pick
The Pharmaceutical Journal
19 September 2025
PrEP programmes & uptake

New BASHH report on PrEP access and uptake in the UK

Editor's pick
i-Base
19 September 2025
Injectable & long-acting PrEP

Can health systems keep pace with HIV prevention’s breakthrough?

Editor's pick
Devex (requires free registration)
15 September 2025
Pharmaceutical industry

Lenacapavir in South Africa: There are mounting concerns over transparency in cost

Editor's pick
Health-E News
15 September 2025
PrEP policies & guidelines

U.S. will fulfill Biden-era pledge to provide lenacapavir PrEP to millions

Editor's pick
Science
8 September 2025
Injectable & long-acting PrEP

Why the medical community is thrilled by U.S. support for a 'breakthrough' HIV drug

Editor's pick
NPR
5 September 2025
Injectable & long-acting PrEP

US: CVS Will Not Cover Long-Acting HIV PrEP Lenacapavir For Now

Editor's pick
POZ
5 September 2025
Injectable & long-acting PrEP

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Editor's pick
Gilead Sciences press release
5 September 2025
Access to healthcare

PrEP Insurance Denials Occur Frequently in U.S., Nationwide Survey Reveals

Editor's pick
TheBodyPro
4 September 2025
Injectable & long-acting PrEP

Twists and turns in the race to be South Africa’s first widely used HIV prevention injection

Editor's pick
Spotlight
4 September 2025
Injectable & long-acting PrEP

Kenya to roll out HIV jab lenacapavir in 2026, not a replacement for anti-retrovirals

Editor's pick
Africa Check
4 September 2025